Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 7712 results

  1. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]

    Awaiting development [GID-TA11629] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development [GID-TA11561] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  6. Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]

    Awaiting development [GID-TA10239] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  8. Compression products for treating venous leg ulcers: late stage assessment

    In development [GID-HTE10048] Expected publication date: 27 August 2025

    Health technology evaluations
    In development

  9. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development [GID-TA10700] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266

    In development [GID-TA11248] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  11. Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211

    In development [GID-TA11201] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  12. Tolebrutinib for treating relapsing multiple sclerosis ID6351

    Awaiting development [GID-TA11333] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]

    In development [GID-TA11398] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Leadless cardiac pacemaker implantation for bradyarrhythmias

    Awaiting development [GID-IPG10340] Expected publication date: 13 November 2025

    Interventional procedures guidance
    Awaiting development